Immune checkpoint inhibitors (ICIs) are highly concerned in the treatment of non-small cell lung cancer (NSCLC). represented by inhibitors of programmed death protein 1 (PD-1) and its ligand (PD-L1). and inhibitors of cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). The introduction of immunotherapy in the treatment of perioperative NSCLC has improved the prognosis to a great ext... https://www.jmannino.com/best-catch-Sophie-Allport-Bee-Blackout-Ready-Made-Eyelet-Curtains-Duck-Egg-special-save/